It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Heparin-induced thrombocytopenia/thrombosis (HIT) is a serious immune reaction to heparins, characterized by thrombocytopenia and often severe thrombosis with high morbidity and mortality. HIT is mediated by IgG antibodies against heparin/platelet factor 4 antigenic complexes. These complexes are thought to activate platelets leading to thrombocytopenia and thrombosis. Here we show that HIT immune complexes induce NETosis via interaction with FcγRIIa on neutrophils and through neutrophil-platelet association. HIT immune complexes induce formation of thrombi containing neutrophils, extracellular DNA, citrullinated histone H3 and platelets in a microfluidics system and in vivo, while neutrophil depletion abolishes thrombus formation. Absence of PAD4 or PAD4 inhibition with GSK484 abrogates thrombus formation but not thrombocytopenia, suggesting they are induced by separate mechanisms. NETs markers and neutrophils undergoing NETosis are present in HIT patients. Our findings demonstrating the involvement of NETosis in thrombosis will modify the current concept of HIT pathogenesis and may lead to new therapeutic strategies.
The pathogenesis of heparin-induced thrombocytopenia and thrombosis (HIT) is mediated by heparin-reactive autoantibodies binding to platelets (thrombocytes). Here the authors show neutrophil activation and NETosis are elevated in patients with HIT, and are essential for thrombosis in HIT mouse models.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Faculty of Medicine, University of New South Wales, Haematology Research Unit, St George and Sutherland Clinical School, Sydney, Australia (GRID:grid.1005.4) (ISNI:0000 0004 4902 0432)
2 The University of Sydney, Sydney Medical School, Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X); The University of Sydney, Centre for Heart Research, Westmead Institute for Medical Research, Sydney, Australia (GRID:grid.1013.3) (ISNI:0000 0004 1936 834X); Westmead Hospital, Department of Cardiology, Sydney, Australia (GRID:grid.413252.3) (ISNI:0000 0001 0180 6477); Victor Chang Cardiac Research Institute, Darlinghurst, Australia (GRID:grid.1057.3) (ISNI:0000 0000 9472 3971)
3 Faculty of Medicine, University of New South Wales, Haematology Research Unit, St George and Sutherland Clinical School, Sydney, Australia (GRID:grid.1005.4) (ISNI:0000 0004 4902 0432); New South Wales Health Pathology, St George and Sutherland Hospitals, Sydney, Australia (GRID:grid.1005.4)